SMi's 13th Annual Controlled Release Conference To Feature Discussion on the Future of Controlled Release Peptide Drug Delivery from Ipsen

Share Article

SMi's 13th annual Controlled Release conference, taking place on 18th - 19th April 2016 in London, will feature an array of case studies focused on topics including the importance of Quality by Design, innovations in Controlled Release, Product Design analysis, New Platforms in Controlled Release Delivery and much more.

SMi's 13th annual Controlled Release conference

Due to the excellent safety profile of poly(lactic-co-glycolic acid) or PLGA particles in humans, and their biodegradability, many studies have focused on the application of these particles as a controlled release vaccine delivery system. Antigenic peptides can be encapsulated into the surface of PLGA particles and the gradual release of loaded antigens from PLGA particles is necessary for the induction of efficient immunity. The co-delivery of antigens and immunostimulants (IS) with PLGA particles can prevent the systemic adverse effects of immunopotentiators and activate both dendritic cells (DCs) and natural killer (NKs) cells, consequently enhancing the therapeutic efficacy of antigen-loaded PLGA particles.
(Source: NCBI, 29 October 2015, ‘Peptide/protein vaccine delivery system based on PLGA particles’,

Against this backdrop, SMi is proud to announce that Ipsen’s Novel Drug Delivery Technologies Director, Andy Lewis, will be delivering a keynote address taking place on Day Two of SMi's 13th annual Controlled Release conference at 09:10 titled ‘The future of controlled release peptide drug delivery’. His presentation will cover the following key points:

Review of routes of delivery of currently marketed peptide products
Novel peptide dosage forms currently in development
Future innovations in peptide delivery

Speaker Panel includes:
David Elder, Due Diligence Director, GlaxoSmithKline
Andy Lewis, Director Novel Drug Delivery Technologies, Ipsen
Sachin Mittal, Senior Principal Scientist, Merck
Marianne Ashford, Principal Scientist Drug Targeting, AstraZeneca
Sune Andersen, Principal Scientist, Novo Nordisk

To view the full speaker line-up and conference programme, visit

Plus, don't miss two interactive post-conference workshops taking place on 20th April 2016:

A: QbD/PAT Driven Controlled Release Design and Development | Led by Cristiana Campa, Head, Quality by Design Integration, GlaxoSmithKline and Jerome Mantanus, Senior Scientist QbD/PAT Drug Product Formulation, UCB Pharma

B: Exploring Controlled Release Drug Delivery Methods | Led by Rene Holm, Senior Director, Lundbeck; Clive Wilson, Professor of Pharmaceutics, University of Strathclyde; Ijeoma Uchegbu, Scientific Secretary CRS, Chair in Pharmaceutical Nanoscience, University Of London and CEO, Nanometrics

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Vinh Trinh
Follow >

Visit website